Liver cancer trial tests new chemo combo without embolization
NCT ID NCT03727633
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tested a liver-directed chemotherapy using idarubicin mixed with lipiodol (a fatty contrast agent) injected directly into the liver artery. The goal was to see if this could control non-spreading liver cancer in 44 patients with cirrhosis. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
idarubicin and lipiodol
What this could lead to
If it works, this could offer a new way to control liver cancer in patients who cannot have surgery or other standard treatments.
What could go wrong
This is an early phase 2 trial with only 44 participants, and it was terminated early. The treatment may not control the disease or could cause side effects like liver damage or low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU d'Angers
Angers, 49933, France
-
CHU de Dijon
Dijon, 21079, France
-
CHU de Montpellier
Montpellier, 34295, France
-
CHU de Nice
Nice, 06202, France